Rigel Pharmaceuticals, Inc.RIGLNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank62
3Y CAGR-46.8%
5Y CAGR-32.0%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-46.8%/yr
Quarterly compound
5Y CAGR
-32.0%/yr
Recent deceleration
Percentile
P62
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 3.65% |
| Q3 2025 | -1.10% |
| Q2 2025 | 5.56% |
| Q1 2025 | -6.11% |
| Q4 2024 | 9.16% |
| Q3 2024 | -3.58% |
| Q2 2024 | -1.41% |
| Q1 2024 | 5.96% |
| Q4 2023 | 8.02% |
| Q3 2023 | -5.51% |
| Q2 2023 | -5.13% |
| Q1 2023 | -13.81% |
| Q4 2022 | 24.23% |
| Q3 2022 | -4.02% |
| Q2 2022 | -1.53% |
| Q1 2022 | 11.77% |
| Q4 2021 | 7.16% |
| Q3 2021 | 2.23% |
| Q2 2021 | 1.16% |
| Q1 2021 | 1.39% |
| Q4 2020 | 25.17% |
| Q3 2020 | -7.88% |
| Q2 2020 | 2.66% |
| Q1 2020 | 0.64% |
| Q4 2019 | 1.05% |
| Q3 2019 | -0.48% |
| Q2 2019 | -8.71% |
| Q1 2019 | -6.66% |
| Q4 2018 | 18.27% |
| Q3 2018 | 5.85% |
| Q2 2018 | 26.53% |
| Q1 2018 | -7.93% |
| Q4 2017 | 84.40% |
| Q3 2017 | 1.62% |
| Q2 2017 | 5.53% |
| Q1 2017 | 3.59% |
| Q4 2016 | 56.93% |
| Q3 2016 | -4.52% |
| Q2 2016 | 7.94% |
| Q1 2016 | -6.31% |